Response and relapse (N = 65)
| Total . | n . | % . |
|---|---|---|
| Overall CR (CR + CRi)* | 64 | 98.5 |
| CR | 62 | 95.4 |
| CR with incomplete count recovery | 2 | 3.1 |
| Refractory | 1 | 1.5 |
| Overall CR by course | 64 | |
| I (n = 65) | 36† | 55.4 |
| IIA (n = 60) | 27 | 41.5 |
| IIB (n = 1) | 0 | 0 |
| III (n = 2) | 1 | 1.5 |
| Molecular response end of course IV | 43 | |
| CMR | 17 | 39.5 |
| MMR | 12 | 27.9 |
| Less than MMR | 14 | 32.6 |
| Cytogenetic response end of course IV | 34 | |
| CCyR | 27 | 79.4 |
| Less than CCyR | 7 | 20.6 |
| Relapse during each course | 25 | |
| I | 0 | 0 |
| IIA/IIB/III | 0 | 0 |
| IV: CNS prophylaxis | 2 | 8 |
| V | 3 | 12 |
| Allogeneic HCT (n = 20) | 1 | |
| Autologous HCT (n = 7) | 2 | |
| Chemotherapy (n = 11) | 0 | |
| VI: maintenance | 2 | 8 |
| Allogeneic HCT (n = 18) | 0 | |
| Autologous HCT (n = 4) | 1‡ | |
| Chemotherapy (n = 9) | 1§ | |
| Follow-up after completion of maintenance | 10 | 40 |
| Allogeneic HCT (n = 13) | 4‡(1),§(1) | |
| Autologous HCT (n = 3) | 1 | |
| Chemotherapy (n = 6) | 3‡(1),§(1) | |
| Skipped course V (n = 3) | 2 | |
| Off-protocol therapy | 8 | 32 |
| Adverse events | 4 | |
| Patient refusal/noncompliance | 3‡(1) | |
| Off-protocol allogeneic HCT | 1‡ |
| Total . | n . | % . |
|---|---|---|
| Overall CR (CR + CRi)* | 64 | 98.5 |
| CR | 62 | 95.4 |
| CR with incomplete count recovery | 2 | 3.1 |
| Refractory | 1 | 1.5 |
| Overall CR by course | 64 | |
| I (n = 65) | 36† | 55.4 |
| IIA (n = 60) | 27 | 41.5 |
| IIB (n = 1) | 0 | 0 |
| III (n = 2) | 1 | 1.5 |
| Molecular response end of course IV | 43 | |
| CMR | 17 | 39.5 |
| MMR | 12 | 27.9 |
| Less than MMR | 14 | 32.6 |
| Cytogenetic response end of course IV | 34 | |
| CCyR | 27 | 79.4 |
| Less than CCyR | 7 | 20.6 |
| Relapse during each course | 25 | |
| I | 0 | 0 |
| IIA/IIB/III | 0 | 0 |
| IV: CNS prophylaxis | 2 | 8 |
| V | 3 | 12 |
| Allogeneic HCT (n = 20) | 1 | |
| Autologous HCT (n = 7) | 2 | |
| Chemotherapy (n = 11) | 0 | |
| VI: maintenance | 2 | 8 |
| Allogeneic HCT (n = 18) | 0 | |
| Autologous HCT (n = 4) | 1‡ | |
| Chemotherapy (n = 9) | 1§ | |
| Follow-up after completion of maintenance | 10 | 40 |
| Allogeneic HCT (n = 13) | 4‡(1),§(1) | |
| Autologous HCT (n = 3) | 1 | |
| Chemotherapy (n = 6) | 3‡(1),§(1) | |
| Skipped course V (n = 3) | 2 | |
| Off-protocol therapy | 8 | 32 |
| Adverse events | 4 | |
| Patient refusal/noncompliance | 3‡(1) | |
| Off-protocol allogeneic HCT | 1‡ |